Vericel Co. (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 8.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 472,963 shares of the biotechnology company's stock after purchasing an additional 37,784 shares during the period. Geneva Capital Management LLC owned about 0.99% of Vericel worth $16,842,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in VCEL. Knights of Columbus Asset Advisors LLC raised its stake in Vericel by 98.5% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 226,015 shares of the biotechnology company's stock valued at $8,048,000 after acquiring an additional 112,169 shares during the period. Federated Hermes Inc. grew its holdings in Vericel by 21.2% during the 4th quarter. Federated Hermes Inc. now owns 560,419 shares of the biotechnology company's stock valued at $19,957,000 after buying an additional 97,952 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Vericel by 54.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 126,383 shares of the biotechnology company's stock valued at $4,236,000 after buying an additional 44,507 shares in the last quarter. Legato Capital Management LLC grew its holdings in Vericel by 20.6% during the 4th quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company's stock valued at $368,000 after buying an additional 1,765 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its holdings in Vericel by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company's stock valued at $83,326,000 after buying an additional 109,215 shares in the last quarter.

Vericel Stock Performance

VCEL traded down $0.55 during midday trading on Friday, hitting $48.10. The stock had a trading volume of 315,714 shares, compared to its average volume of 523,110. The company has a market cap of $2.33 billion, a P/E ratio of -534.44 and a beta of 1.74. The business has a fifty day moving average of $47.37 and a 200 day moving average of $41.76. Vericel Co. has a 1 year low of $30.18 and a 1 year high of $53.05.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. The firm had revenue of $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The business's revenue was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, equities research analysts anticipate that Vericel Co. will post 0.09 earnings per share for the current year.

Insider Activity at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now owns 195,307 shares in the company, valued at $8,708,739.13. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Robert L. Md Zerbe sold 3,278 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the sale, the director now directly owns 23,395 shares of the company's stock, valued at $1,206,480.15. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the sale, the chief executive officer now directly owns 195,307 shares in the company, valued at $8,708,739.13. The disclosure for this sale can be found here. Insiders sold a total of 54,267 shares of company stock worth $2,450,996 over the last quarter. 7.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

VCEL has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a "buy" rating and set a $54.00 target price on shares of Vericel in a report on Tuesday, March 26th. TheStreet raised Vericel from a "d+" rating to a "c-" rating in a report on Monday, January 29th. Finally, HC Wainwright boosted their price objective on Vericel from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.80.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.